TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01599520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)
Description: Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Only
Description: Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health.
Study: NCT00330876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study: NCT05088642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet
Study: NCT02164929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam up to 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam up to 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam up to 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam up to 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane to keep a bispectral index of between 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane to keep a bispectral index of between 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane to keep a bispectral index of between 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane to keep a bispectral index of between 40-60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with 10 mL of plain ropivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with 10 mL of plain ropivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with 10 mL of plain ropivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with 10 mL of plain ropivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1:200,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 400-800 mcg Hydromorphone will be given preoperatively
Study: NCT02969187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT04717518

Intervention type: OTHER
Intervention: Measurement of Pain
Description: Patients will fill out a brief survey concerning the current visit to the ED.

Intervention type: OTHER
Intervention: Measurement of Pain
Description: Patients will fill out a brief survey concerning the current visit to the ED.
Study: NCT03668600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
Study: NCT02793440

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cortivazol treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar traction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction
Study: NCT01512836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching
Study: NCT01438489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Description: Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg
Description: Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Study: NCT05699889

Intervention type: OTHER
Intervention: Data collection
Description: acute kidney injury and tubular dysfunction

Intervention type: OTHER
Intervention: Data collection
Description: acute kidney injury and tubular dysfunction
Study: NCT03437382

Intervention type: DEVICE
Group type: OTHER
Intervention: Quirem Medical Holmium-166 radioembolization microspheres
Description: radioembolisation as adjuvant treatment to RFA
Study: NCT01147289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextralgen
Description: Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Study: NCT02887664

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
Study: NCT00865059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg Tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 800 mg Tablets, single dose
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Study: NCT02446314

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry Powder - 450mg
Description: Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry Powder - 900 mg
Description: Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry extract 100mg
Description: Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
Study: NCT02036242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sole local anesthetic
Description: 0.125% ropivacaine 10-15 ml every 1h during labor delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil (Opioid plus local anesthetic)
Description: Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT00984971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Topical gel applied rectally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo
Description: Placebo gel applied rectally

Intervention type: DRUG
Group type: OTHER
Intervention: Open label tenofovir tablet
Description: All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
Study: NCT03506321

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: chromoendoscopy, high definition white light and narrow band imaging
Description: Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
Study: NCT03382977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Study: NCT05526690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg dose of immediate-release metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg dose of immediate-release metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: 10 mg dose of CIN-107
Study: NCT02439996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (1g/kg,once)
Description: Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (1g/kg,twice)
Description: Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (2g/kg.once)
Description: Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study: NCT01105676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Two skin biopsies will be taken one time
Study: NCT03083704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 1 Process 2)
Description: factor Xa inhibitor antidote

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 MG
Description: factor Xa inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 2)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 1 Process 3)
Description: factor Xa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 1 Process 3)
Description: factor Xa inhibitor antidote

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 10 MG
Description: factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: factor Xa inhibitor
Study: NCT01792349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARFISH intervention
Description: STARFISH is a behavioural intervention to encourage the user to become more physically active
Study: NCT01471015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: 10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: 2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
Study: NCT04069195

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA supplement
Description: Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil: Soybean Oil
Description: Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
Study: NCT03953430

Intervention type: OTHER
Intervention: Gait analysis

Intervention type: OTHER
Intervention: Gait analysis
Study: NCT02742064

Intervention type: OTHER
Intervention: Cogito Companion Mobile Phone Application

Intervention type: OTHER
Intervention: Cogito Companion Mobile Phone Application

Intervention type: OTHER
Intervention: Cogito Companion Mobile Phone Application
Study: NCT01937533

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging using an endovaginal receiver coil
Study: NCT03606993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement
Description: For Mother-infant dyads enrolled into the LIF arm, mother receives one \~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
Study: NCT03533972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: ashwagandha capsules given to the subjects twice daily after meals for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules given twice daily after meals for 1 month
Study: NCT02942914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT04798937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: a health education program based on motivational interviewing provided by a nurse